Harpoon Therapeutics, Inc. (NASDAQ:HARP) Major Shareholder Ansbert Gadicke Sells 8,972 Shares


Share on StockTwits

Harpoon Therapeutics, Inc. (NASDAQ:HARP) major shareholder Ansbert Gadicke sold 8,972 shares of the stock in a transaction dated Wednesday, April 21st. The stock was sold at an average price of $18.97, for a total value of $170,198.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Ansbert Gadicke also recently made the following trade(s):

  • On Monday, April 19th, Ansbert Gadicke sold 10,056 shares of Harpoon Therapeutics stock. The stock was sold at an average price of $19.30, for a total value of $194,080.80.
  • On Friday, April 16th, Ansbert Gadicke sold 5,847 shares of Harpoon Therapeutics stock. The stock was sold at an average price of $19.86, for a total value of $116,121.42.
  • On Monday, April 12th, Ansbert Gadicke sold 20,628 shares of Harpoon Therapeutics stock. The stock was sold at an average price of $21.02, for a total value of $433,600.56.
  • On Friday, April 9th, Ansbert Gadicke sold 10,300 shares of Harpoon Therapeutics stock. The stock was sold at an average price of $23.67, for a total value of $243,801.00.

Shares of Harpoon Therapeutics stock traded up $0.76 during midday trading on Thursday, hitting $20.51. 213,830 shares of the company were exchanged, compared to its average volume of 283,082. The firm has a market cap of $664.75 million, a P/E ratio of -9.63 and a beta of 0.87. Harpoon Therapeutics, Inc. has a 52 week low of $10.55 and a 52 week high of $25.24. The firm has a 50 day simple moving average of $20.05 and a 200-day simple moving average of $18.02.

Harpoon Therapeutics (NASDAQ:HARP) last posted its earnings results on Tuesday, March 9th. The company reported ($0.45) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.54) by $0.09. Harpoon Therapeutics had a negative return on equity of 68.32% and a negative net margin of 434.74%. As a group, sell-side analysts anticipate that Harpoon Therapeutics, Inc. will post -2.12 earnings per share for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of HARP. BlackRock Inc. raised its position in Harpoon Therapeutics by 20.3% in the 4th quarter. BlackRock Inc. now owns 1,364,212 shares of the company’s stock valued at $22,659,000 after purchasing an additional 230,240 shares during the last quarter. JPMorgan Chase & Co. raised its position in Harpoon Therapeutics by 2,058.9% in the 4th quarter. JPMorgan Chase & Co. now owns 85,103 shares of the company’s stock valued at $1,414,000 after purchasing an additional 81,161 shares during the last quarter. GSA Capital Partners LLP raised its position in Harpoon Therapeutics by 159.5% in the 4th quarter. GSA Capital Partners LLP now owns 83,673 shares of the company’s stock valued at $1,390,000 after purchasing an additional 51,430 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Harpoon Therapeutics by 53.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 109,016 shares of the company’s stock valued at $1,853,000 after purchasing an additional 37,754 shares during the last quarter. Finally, Chartwell Investment Partners LLC bought a new position in Harpoon Therapeutics in the 4th quarter valued at $475,000. Hedge funds and other institutional investors own 79.03% of the company’s stock.

HARP has been the topic of several research reports. Robert W. Baird reaffirmed a “buy” rating and issued a $35.00 target price on shares of Harpoon Therapeutics in a research report on Monday, March 22nd. HC Wainwright reissued a “buy” rating and set a $31.00 price objective on shares of Harpoon Therapeutics in a report on Wednesday, December 23rd. Zacks Investment Research lowered Harpoon Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, March 15th. Finally, SVB Leerink reduced their price objective on Harpoon Therapeutics from $31.00 to $29.00 and set an “outperform” rating for the company in a research report on Wednesday, March 17th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $30.78.

Harpoon Therapeutics Company Profile

Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer.

Read More: Percentage Gainers

Insider Buying and Selling by Quarter for Harpoon Therapeutics (NASDAQ:HARP)

Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.